Compare ETSY & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETSY | IBRX |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.1B |
| IPO Year | 2015 | 2015 |
| Metric | ETSY | IBRX |
|---|---|---|
| Price | $55.95 | $8.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 27 | 6 |
| Target Price | ★ $60.00 | $12.50 |
| AVG Volume (30 Days) | 4.3M | ★ 31.8M |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $441,231,000.00 | $113,288,000.00 |
| Revenue This Year | N/A | $88.57 |
| Revenue Next Year | $3.48 | $146.98 |
| P/E Ratio | $40.74 | ★ N/A |
| Revenue Growth | 20.90 | ★ 668.31 |
| 52 Week Low | $40.05 | $1.83 |
| 52 Week High | $76.52 | $12.43 |
| Indicator | ETSY | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.23 | 54.98 |
| Support Level | $55.62 | $2.23 |
| Resistance Level | $57.16 | $12.43 |
| Average True Range (ATR) | 2.64 | 1.27 |
| MACD | 0.88 | -0.16 |
| Stochastic Oscillator | 83.07 | 41.62 |
Etsy operates a top-10 e-commerce marketplace in the US and the UK, with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $12.5 billion in 2024 consolidated gross merchandise volume, Etsy has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. The firm connects about 95 million buyers and 8 million sellers on its marketplace properties: Etsy and Depop (clothing resale).
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.